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HOX genes have emerged as critical effectors of leukemogenesis,
but the mechanisms that regulate their expression in leukemia are
not well understood. Recent data suggest that the caudal ho-
meobox transcription factors CDX1, CDX2, and CDX4, developmen-
tal regulators of HOX gene expression, may contribute to HOX
gene dysregulation in leukemia. We report here that CDX4 is
expressed normally in early hematopoietic progenitors and is
expressed aberrantly in 25% of acute myeloid leukemia (AML)
patient samples. Cdx4 regulates Hox gene expression in the adult
murine hematopoietic system and dysregulatesHox genes that are
implicated in leukemogenesis. Furthermore, bone marrow progen-
itors that are retrovirally engineered to express Cdx4 serially
replate in methylcellulose cultures, grow in liquid culture, and
generate a partially penetrant, long-latency AML in bone marrow
transplant recipients. Coexpression of the Hox cofactor Meis1a
accelerates the Cdx4 AML phenotype and renders it fully pene-
trant. Structure–function analysis demonstrates that leukemic
transformation requires intact Cdx4 transactivation and DNA-
binding domains but not the putative Pbx cofactor interaction
motif. Together, these data indicate that Cdx4 regulates Hox gene
expression in adult hematopoiesis and may serve as an upstream
regulator of Hox gene expression in the induction of acute leuke-
mia. Inasmuch as many human leukemias show dysregulated
expression of a spectrum of HOX family members, these collective
findings also suggest a central role for CDX4 expression in the
genesis of acute leukemia.
transcriptional regulation  Hox regulation  leukemogenesis  self-renewal
The CDX homeobox transcription factors are homologues of theDrosophila Caudal gene (1) and are thought to function as
master regulators ofHOX gene expression. Consensus binding sites
for the three Cdx homologues Cdx1, Cdx2, and Cdx4 are present in
the promoters of multiple Hox genes (2), and several lines of
evidence highlight the importance of CDX family members as
upstream regulators of HOX gene expression. These include a key
role for CDX2 in regulation of HOX gene expression in the
epithelium of the gastrointestinal tract (3), and similar homeotic
transformations in Cdx1-, Cdx2-, and Cdx4-deficient mice and
zebrafish to those observed in Hox-deficient animals (4, 5).
CDX family members are also important in hematopoietic
development. Loss of function of Cdx4 in zebrafish results in a
bloodless phenotype, associated with homeotic transformation, and
marked abnormalities in Hox gene expression pattern during de-
velopment (5, 6). These phenotypes can be rescued, in part, by
expression of Hox family members, further supporting a role for
Cdx4 as an upstream positive regulator of Hox gene expression.
Additional data support the role of CDX4 in hematopoietic de-
velopment and suggest an epistatic relationship betweenCDX4 and
MLL. For example, overexpression of Cdx4 in ES cells increases
hematopoietic colony formation from embryoid bodies, up-
regulates aHox gene expression program, and rescuesMll-deficient
hematopoiesis in vitro (5, 7, 8). CDX genes also have been impli-
cated in acute myeloid leukemia (AML). For example, an acquired
t(12;13) in AML results in overexpression of CDX2 as a conse-
quence of juxtaposition of CDX2 to the ETV6 promoter (9), and
overexpression of Cdx2 results in AML in a murine bone marrow
(BM) transplantation model (10).
Hox genes are expressed in hematopoietic precursors, with
preferential expression in self-renewing hematopoietic stem cells
(HSC) and are down-regulated during differentiation (11). Their
importance in normal blood formation and maintenance has been
demonstrated in gene-targeting studies in which abnormalities of
multiple hematopoietic lineages have been observed in mice defi-
cient in individual Hox genes (12). Moreover, overexpression of
specific Hox genes, such as HOXB4 or HOXA9, is associated with
expansion of the HSC compartment in vitro and in vivo and results
in enhanced competitive repopulating activity in murine transplan-
tation experiments (13, 14).
Substantial evidence also has linked aberrant expression ofHOX
genes to the pathogenesis of acute leukemia. For example, fusions
of theHOXA9 orHOXD13 genes withNUP98, a gene that encodes
a component of the nuclear pore complex, have been described in
AML, and expression of NUP98–HOXA9 or NUP98–HOXD13
results in AML in murine models of disease (15, 16). In addition,
overexpression of individual HOX family members, including
HOXB3 (17), HOXB8 (18), or HOXA10 (19), by retroviral ex-
pression or retroviral insertional mutagenesis also generates AML
in murine models. Although these findings show the relevance of
dysregulated expression of a single HOX family member in AML,
translocations involving individual HOX family members are rare.
Moreover, in themajority of cases of AML and some cases of acute
lymphoblastic leukemia (ALL) there is evidence for widespread
dysregulated expression of multiple HOX family members, a phe-
notype associated with a poor prognosis (20, 21). This finding
suggests that dysregulation of HOX gene expression in acute
leukemias may involve upstream master regulators. In 5–10% of
cases, dysregulation can be explained by the expression of fusion
proteins involving the mixed-lineage leukemia (MLL) gene that
have been shown to mediate their effects in part through up-
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regulation of several HOX genes (20, 22). In cases of acute
lymphoblastic leukemia, dysregulation of HOX genes also is asso-
ciated with expression of CALM–AF10 or fusions of TCRB and
genes from the HOXA cluster (23). However, the upstream effec-
tors of dysregulated HOX gene expression in the majority of acute
leukemias are not known.
During development, Cdx family members are thought to play an
important role in Hox gene regulation. Hox gene expression is
tightly controlled in a spatiotemporal manner to confer positional
information to the axial and paraxial tissues as they emerge from
the posterior portion of the vertebrate embryo (24). This process is
not fully understood at the molecular level, but morphogens such
as fgf, retinoic acid (RA), and Wnt signals are thought to be
involved in the initiation of expression, with establishment of the
Hox expression domains occurring through the actions of Cdx
proteins along gradients of these morphogens. Maintenance ofHox
gene expression subsequently occurs via complex interactions
of Trithorax group proteins, such as Mll, and Polycomb group
proteins.
Based on these collective observations, we hypothesized that
CDX4 might be a critical upstream regulator of HOX gene expres-
sion in the hematopoietic system, and that overexpression of CDX4
might result in widely dysregulated HOX gene expression and a
leukemia phenotype. We tested this hypothesis in cell culture and
murine BM transplantation assays and assayedCDX4 expression in
BM samples isolated from a heterogeneous cohort of patients
with AML.
Results
Cdx4 Is Expressed During Adult Hematopoiesis and in AML Patient
Samples. Cdx2 is not expressed in adult BM (9), but the expression
pattern of Cdx4 in adult hematopoiesis is unknown. We performed
real-time quantitative RT-PCR (qRT-PCR) by using Cdx4-specific
primers in murine BM, peripheral blood, and flow-sorted hema-
topoietic progenitor cells. Cdx4 is preferentially expressed in prim-
itive stem and progenitor cells with expression down-regulated in
more differentiated cell types (Fig. 1a). In addition, CDX4 tran-
scripts were detectable in BM or peripheral blood mononuclear
cells from 10 of 44 patients (23%) with AML (Fig. 1b): 3 of 16
patients with normal cytogenetics, 3 of 4 patients with trisomy 8 as
the sole cytogenetic abnormality, 1 of 2 patients with
t(9;11)(p22;q23), and 3 of 7 patients with t(15;17)(q22;q1121).
Themedian expression level for theCDX4-positive samples was 130
(range 28–747). No CDX4 expression was detectable in 1 patient
with t(11;19)(q23;p13), 2 patients with inv(16)(p13q22), and 12
patients with complex karyotypes, defined as three or more cyto-
genetic abnormalities in the absence of t(8;21)(q22;q22), inv(16),
t(15;17), or t(11q23).
Expression of Cdx4 Confers Serial Replating Activity to Murine BM
Cells and Generates AML in aMouseModel.Wenext clonedCdx4 into
retroviral expression vectors and demonstrated that transient trans-
fection of Cdx4 in 293T cells resulted in expression of the expected
32-kDa protein as assessed by Western blot analysis (Fig. 6a, which
is published as supporting information on the PNAS web site).
Myc-tagged Cdx4 was demonstrated to be localized to the nucleus,
consistent with its function as a transcription factor (Fig. 6b).
Transduction of primary murine BM cells with Cdx4 conferred
serial replating activity in the absence of stroma (Fig. 2a), a
surrogate assay for transformationself-renewal potential (25). In
control experiments, nontransduced cells did not replate. Cytospins
of single colonies derived from the fifth round of replating of
Cdx4-transduced BM demonstrated primitive myelomonocytic
morphology (Fig. 2b). These cells were capable of growth in liquid
culture in the presence of IL-3 (Fig. 2c).
We next tested the leukemogenic potential of Cdx4 in vivo. BM
cells derived from 5-fluorouracil-treated BALBc mice were trans-
Fig. 1. Cdx4CDX4 is expressed during murine hematopoiesis and in human
acute leukemias. (a) The expression pattern of Cdx4 in flow-sorted stem and
progenitor cells and in unfractionated BM and peripheral blood (PB) is shown
(relative to GAPDH). HSC, hematopoietic stem cells; CMP, common myeloid
progenitor; GMP, granulocyte–monocyte progenitor; MEP, megakaryocyte–
erythroid progenitor. (b) Dot plot shows expression level of CDX4 in primary
samples isolated from AML patients with diverse karyotypes.
Fig. 2. In vitro analyses demonstrate that Cdx4 can confer properties of
self-renewal to hematopoietic progenitor cells. (a) Bar chart showing results
of serial replating experiments. In contrast to primary BM cells transduced
with empty Neo vector (control) or with Meis1a alone, cells transduced with
either Cdx4 alone or Cdx4Meis1a demonstrated serial replating ability up to
the fifth plating. (b) Immature myelomonocytic morphology of cells derived
from colonies of the fifth round of plating for Cdx4- and Cdx4Meis1a-
transduced BM cells. (c) Line graph demonstrating the sustained growth and
proliferation of both Cdx4- and Cdx4Meis1a-transduced BM cells for over 6
weeks in IL3-supplemented media.











duced with MSCV-Cdx4-IRES-GFP and injected intravenously
into lethally irradiated syngeneic recipient mice, and the trans-
planted mice were observed for disease development. Half of the
transplant recipients developed AML, with a median latency of
300 days posttransplantation (Fig. 3a), that was characterized by
an elevated (5- to 10-fold) peripheral white blood (WBC) count, the
presence of blasts in the peripheral blood, and splenomegaly
(average spleen weight of 0.9 g; Fig. 3b). Histopathological
analysis showed extensive infiltration of the BM, liver, and spleen
with immature myeloid cells (Fig. 3c). Integration of the MSCV-
Cdx4-GFPproviruswas demonstrated by Southern blotting analysis
(Fig. 7c Left, which is published as supporting information on the
PNAS web site). Immunophenotypic characterization of leukemic
BM and spleen in Cdx4 mice showed a predominance of Mac1
and Gr1 cells and a reduction of lymphoid cells (data not shown)
in the GFP-positive fraction. Both BM and spleen leukemic cells
also showed a large fraction (12–20%) of cKit, Mac1 early
myeloid cells (Fig. 3d). The leukemia generated was transplantable
to secondary recipients resulting in a similar phenotype 6–8 weeks
after transplantation (Fig. 7).
Meis1a Cooperates with Cdx4 to Transform Hematopoietic Cells.
Gene expression studies in human AML (21), retroviral insertional
mutagenesis screens inmice (26), and retroviral mousemodels (27)
have demonstrated Meis1a to be a cofactor for leukemic transfor-
mation by Hox genes. We hypothesized that Meis1a might coop-
erate with Hox genes whose expression was induced by Cdx4 or
might cooperate as a cofactor through direct interactions with
Cdx4. To test this hypothesis, murine BM cells were cotransduced
with MSCV-Cdx4-Neo and MSCV-Meis1a-Puro, and serial replat-
ing was performed after selection in G418 and puromycin (Fig. 2a).
Colony numbers were statistically significantly increased in cells
cotransduced with Cdx4 and Meis1a (Cdx4Meis1a cells) when
compared with cells transduced with Cdx4 alone (P  0.04).
Similarly, in liquid culture, the growth rate of Cdx4Meis1a cell
lines was consistently higher than that of Cdx4 lines (Fig. 2c).
Cooperation between Meis1a and Cdx4 also was demonstrated
in vivo. BM cotransduced with Cdx4 and Meis1a generated a
leukemia that, in contrast with Cdx4 alone, was fully penetrant with
a reducedmedian survival (170 days, P 0.01; Fig. 3a). However,
leukemia induced by Cdx4 and Meis1a was indistinguishable by
histological and immunophenotypic examination from that induced
by Cdx4 alone (Fig. 3 c and d). This disease also could be
transplanted to secondary recipients and generated leukemia more
rapidly than Cdx4 alone (Fig. 7). Cooperation betweenMeis1a and
Cdx4 was confirmed by Southern blot analysis showing retroviral
integration of each of the respective retroviruses in leukemic cells
derived from secondary recipients transplanted at limiting dilution
(Fig. 7c).
Fig. 3. Overexpression of Cdx4
generates AML in a mouse model.
(a) Survival curve of mice trans-
planted with BM cells transduced
with either Cdx4 or Cdx4Meis1a
(n  10 for each). The mice trans-
planted with cells transduced with
Cdx4Meis1a showed increased
penetrance and a significant reduc-
tion in the disease latency (P 0.01
by log-rank analysis). (b) Analysis
of white blood cell (WBC) counts
and spleen weight in mice trans-
planted with BM cells transduced
with Cdx4 or Cdx4Meis1a. Higher
white blood counts and spleen
weights were observed in mice
transplanted with Cdx4Meis1a-
transduced vs. Cdx4-transduced
alone BM cells. (c) Histopathology
of Cdx4- and Cdx4Meis1a-trans-
duced BM transplanted mice. BM
sections displaying marked hyper-
cellularity and effacement of nor-
mal marrow architecture by a prom-
inent population of immature
myelomonocytic cells and blast
forms along with extensive infil-
tration of the liver are shown and
demonstrate similar histology. (Mag-
nification: Upper, 100; Lower,
600.) (d) Flow-cytometric analysis
of GFP-positive leukemic BM and
spleen cells isolated from the trans-
planted mice. Similar patterns of
myeloid expansion were seen for
Cdx4- and Cdx4Meis1a-trans-
planted mice.
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Transformation by Cdx4 Requires Intact Transactivation and Home-
odomains and Dysregulates a Hox Gene Expression Program. To
assess the structural requirements for Cdx4 transformation, muta-
tions that abrogate three functional motifs of Cdx4 were generated.
These motifs included a mutation deleting the caudal activation
domain (Cdx4delCAD) and a point mutant (Cdx4N221S) that
abrogates homeodomain DNA-binding activity (Fig. 4a). Pbx pro-
teins are Hox cofactors that enhance the DNA-binding affinity and
specificity of homeobox proteins and bind to clustered and non-
clustered homeoproteins through a highly conserved consensus site
(28, 29). Cdx4 contains a Pbx consensus binding site, and this
putative site was abrogated in the Cdx4W157A point mutant.
Protein expression was demonstrated for each mutant in 293T cells
(Fig. 6), and the ability to confer serial replating activity to
transduced murine BM cells was tested. The Cdx4W157A mutant,
but not the Cdx4delCAD or Cdx4N221S mutants, conferred serial
replating activity. Based on the evidence that this mutation disrupts
a putative Pbx binding site (28, 29), these findings are consistent
with the hypothesis that the Pbx interaction motif is dispensable for
transformation. Coexpression of Meis1a did not rescue serial
replating activity of the Cdx4delCAD or Cdx4N221S mutants (Fig.
4b). In vivo BM transplantation experiments confirmed that the
caudal activation domain and the DNA-binding capacity of the
Cdx4 homeodomain, but not the putative Pbx binding site, were
required for transformation by Cdx4 (data not shown).
Cdx4 regulates Hox gene expression during embryogenesis and
developmental hematopoiesis (5). To determine whether leukemic
transformation by expression of Cdx4 also involved dysregulation of
Hox genes, real-time qRT-PCRwas used tomeasure the expression
level of a set of Hox genes previously implicated in leukemia.
5-Fluorouracil-treatedmurine BMcells enriched for hematopoietic
progenitors were transduced withMSCV-Cdx4-Neo, MSCV-Cdx4-
Neo and MSCV-Meis-1a-Puro, or MSCV-Neo constructs. Cells
were selected in G418 (Cdx4-Neo, MSCV-Neo) or G418 and
puromycin (Cdx4-Neo and Meis1a-Puro) for 1 week. In addition,
total BM from leukemic mice transplanted with either Cdx4- or
Cdx4Meis1a-transduced cells also was harvested. Total RNAwas
isolated from these cellular populations, and cDNA was prepared.
In Cdx4- or Cdx4Meis1a-transduced progenitor cells, a specific
subset of Hox genes were up-regulated, including Hoxa6, Hoxa7,
Hoxa9, Hoxb8, Hoxb4, and Hoxc6 (Fig. 5a). Hox genes also were
dysregulated in leukemic BM with up-regulation of Hoxb4 and
Hoxb6 and down-regulation ofHoxa7,Hoxa9, andHoxa10 (Fig. 5b).
However, in both the immediately transduced progenitors and the
leukemicBM, therewas no apparent additive effect of coexpression
of Meis1a on the level or pattern of Hox gene expression. These
findings indicate that Cdx4 regulates Hox gene expression in adult
as well as developmental hematopoiesis and are consistent with the
hypothesis that Cdx4-induced leukemogenesis is mediated, at least
in part, through dysregulation of Hox family members.
Discussion
HOX gene expression is frequently dysregulated in human acute
leukemias, and the available evidence suggests a causal relationship
between expression of certain HOX family members and leuke-
mogenesis. However, the molecular mechanisms that mediate
aberrant HOX gene expression are known only for a minority of
leukemias, namely those involving rearrangement of theMLL gene
or rearrangement of actual specific HOX genes. In this report, we
demonstrate that Cdx4, a nonclustered homeobox transcription
factor associated with regulation of Hox genes during hematopoi-
etic development, can generateAML in amurinemodel, both alone
and in cooperation with the Hox cofactor Meis1a. Cdx4-
transforming activity depends on an intact transactivation domain
and an intact homeodomain, whereas binding of the cofactor Pbx1
is dispensable for transformation. In addition, we have observed
that expression of Cdx4 results in dysregulated expression of a
spectrum of Hox genes in adult hematopoietic progenitors and
Fig. 4. Structure–function analysis of Cdx4. (a) Schematic describing various
Cdx4deletion and point mutations generated to evaluate the functional require-
ment of various protein domains in Cdx4-mediated transformation. (b) Bar graph
showing results of serial replating experiments testing the transformation ability
of Cdx4 mutants. Cdx4delCAD and Cdx4-N221S are indispensable for the self-
renewal ability of Cdx4. However, BM cells transduced with Cdx4-W157A con-
tinue forming colonies up to the fourth plate, suggesting that the Pbx interaction
domain is dispensable for the transformationself-renewal ability of Cdx4.
Fig. 5. Expression of Cdx4 generates a Hox gene expression program in adult
hematopoietic progenitors. Bar graphs showing expression relative to 18S ribo-
somal RNA of a selected set ofHox genes in BM progenitor cells transduced with
control (MSCV-Neo), Cdx4, or Cdx4Meis1a mice (a) or BM from control (normal)
Cdx4 or Cdx4Meis1a leukaemic mice (b). Represented values are the mean and
SD obtained from three individual experiments performed for each sample.











leukemia cells and have demonstrated that CDX4 is expressed in
leukemic blasts from patients with AML.
Retroviral transduction of BMwith Cdx4 confers serial replating
activity in the absence of stroma, IL-3-dependent growth in liquid
culture, and AML in vivo with incomplete penetrance and long
latency. Coexpression of the Hox cofactor Meis1a with Cdx4
enhances in vitro proliferation of hematopoietic progenitors as
assessed by increased colony number and growth in liquid culture.
Furthermore, coexpression of Cdx4 and Meis1a in vivo results in
AML that is phenotypically indistinguishable from that induced by
Cdx4 alone but with complete penetrance and shortened latency.
Each of these features are reminiscent of transformation by Hoxa9
(27) the expression of which, along with other Hox genes, we have
demonstrated to be increased in Cdx4- and Cdx4Meis1a-
expressing hematopoietic progenitors. These similarities suggest
that a dysregulated Hox expression program is responsible, at least
in part, for the development of the leukemias associated with Cdx4
expression.Downstream interaction between thisHox programand
Meis1a may further facilitate leukemia induction.
Cdx4 previously has been shown to regulateHox gene expression
during development in zebrafish. Cdx4 also is expressed in murine
ES cells during embryoid body formation at days 3 and 4 (5) and
rescues Mll-deficient primitive hematopoiesis in vitro (7). In addi-
tion, overexpression of Cdx4 promotes definitive hematopoiesis
from ES cells in vivo (8). Each of these developmental processes is
enabled, in part, through up-regulation of a specific Hox gene
program that is thought to enhance mesodermal commitment and
competence for hematopoietic specification. We demonstrate here
that endogenous Cdx4 also is expressed in the adult hematopoietic
compartment, with preferential expression in primitive stem and
progenitor cells and down-regulation in more differentiated cell
types. This expression pattern is similar to that described for Hox
genes (11) and further suggests that CDX4may regulateHOX gene
expression in adult hematopoiesis.
We also observed that ectopic expression of Cdx4 results in
dysregulation of a spectrum of Hox family members in the adult
hematopoietic compartment, including Hoxa6, Hoxa7, Hoxa9,
Hoxa10, Hoxb4, Hoxb6, Hoxb8, and Hoxc6. These particular Hox
family members have been implicated in leukemogenesis in other
contexts. For example, it has been proposed by Kersey and
colleagues (30) that there is a ‘‘Hox code’’ that is central to
leukemogenesis mediated by MLL fusion genes and is minimally
defined by the 5 HoxA cluster genes Hoxa5–Hoxa9. In addition,
HOXB4 expression is associated with an increase in the hema-
topoietic stem-cell compartment size and self-renewal (14) and
causes leukemia when coexpressed with Meis1a (31), and mice
that overexpress Hoxb8 in the hematopoietic compartment also
develop leukemia (18). Similarly, overexpression of HOXB6 in
murine BM enhances the self-renewal of myeloid progenitors in
vitro and generates AML in vivo (32). Furthermore, in patients
with B or T cell acute lymphoblastic leukemia, HOXC6 is
overexpressed consistently in patients harboring an MLL trans-
location (20). It also was noted that there were differences
between the pattern of Hox gene expression in directly trans-
duced progenitors and leukemic cells. This finding may reflect
the influence of secondary mutations, extracellular signaling,
niche effects, or differential requirements for dysregulation of
specific Hox family members during the induction and mainte-
nance of leukemia. Together, our findings demonstrate that
expression of Cdx4 dysregulates a Hox gene program in hema-
topoietic tissue, and they are consistent with the hypothesis that
this program has the potential to drive leukemogenesis.
Importantly, the long latency of leukemia from BM cells trans-
duced with cdx4 alone implies that cdx4 dysregulation is not
sufficient to induce leukemia. This conclusion is strengthened by
our observation that coexpression of Cdx4 and Meis1a results in
AML with complete penetrance and shortened latency when
compared with Cdx4 alone. Meis and Pbx are cofactors for ho-
meobox proteins and participate with them in multiprotein tran-
scriptional complexes (33). Pbx interactions enhance the DNA-
binding affinity and specificity of Hox proteins (28, 29). Meis1a
itself binds only to 5 Hox proteins of the Abd-B class (34) but is
thought to interact with other Hox family members through asso-
ciation with Pbx proteins (33). Meis1a also is thought to contribute
to Hox transcriptional activity both by nuclear localization of Pbx
and by directly contributing transactivating activity to the multi-
protein transcriptional complex (35). Because Cdx homeodomain
proteins contain a putative Pbx interaction domain, the observed
cooperation between Cdx4 and Meis1a could be explained by
interaction of Meis1a with Cdx4 through Pbx as a cofactor. How-
ever, this scenario seems unlikely in that deletion of the Cdx4 Pbx
interaction domain had no effect on the ability of Cdx4 to serially
replate. Furthermore, coexpression of Cdx4 and Meis1a did not
affect the absolute level, or pattern, of expression of theHox family
members assayed by qRT-PCR and did not alter the AML phe-
notype. Therefore, it seems more likely that augmentation of the
AML phenotype by coexpression of Meis1a occurs through the
cooperative effects of Meis1a on the function of Hox proteins
up-regulated by Cdx4.
Together, these data suggest that leukemogenesis mediated by
expression of Cdx4 can be attributed to transcriptional targets of
Cdx4, in that mutations predicted to ablate DNA-binding or
transactivation potential of Cdx4 also abrogate leukemogenic po-
tential. These structural requirements are similar to those observed
for transformation mediated by overexpression of Cdx2 (10). In
addition, these data also support the hypothesis that cooperativity
of Cdx4 andMeis1a is caused by potentiation ofHox transcriptional
activity byMeis1a rather than a more direct effect on Cdx4 activity.
Wehave demonstrated thatCdx4 is expressed in the adultmurine
hematopoietic compartment. Furthermore, we also have demon-
strated that CDX4 is expressed in a spectrum of human primary
AML samples. The mechanism of expression of CDX4 is not
known, but there are several pathways that regulate CDX family
member expression during development that also are known to be
mutated or dysregulated in human leukemias. These include the
canonical Wnt-catenin signaling pathway (36), the retinoic acid
signaling pathway, (37) and the FGF pathway (38). It will be of
interest to determine whether CDX family members are critical
effectors of these pathways of transformation.
Materials and Methods
Constructs. Mouse Cdx4 cDNA was cloned into the MSCV-IRES-
GFP and MSCV-pgk-neomycin retroviral vectors. The MSCV-
Meis1a-YFP andMSCV-Meis1a-Puro vectors were a kind gift from
Guy Sauvageau (University of Montreal, Montreal, QC, Canada).
The deletion mutant of Cdx4 was generated by PCR amplification
from the full-length cDNA, and the point mutants were generated
by PCR using the Quickchange XL site-directed mutagenesis kit
(Stratagene, La Jolla, CA). Primers are available on request. All
mutants then were cloned in MSCV-IRES-GFP and MSCV-pgk-
neomycin vectors, sequenced, and used for the further experiments.
Retrovirus Production and BM Transplantation.High-titer retroviral
supernatants were produced, and BM transduction and trans-
plant experiments were performed as described (39).
Serial Replating and Generation of IL-3-Dependent Primary BM Cell
Lines. Serial replating experiments and the generation and count-
ing of cell lines were performed as described (25).
Immunofluorescence Analysis. BaF3 cells were transduced with
MSCV-Cdx4-IRES-GFP retrovirus. After 48 h, transduced cells
were fixed in 4% paraformaldehyde for 20 min, permeabilized with
0.1% Triton X-100, and blocked in 3% BSA plus PBS. Cells were
incubated with anti-myc polyclonal antibody (Cell Signaling Tech-
nology, Danvers, MA) overnight, washed, and incubated with
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secondary antibody (Cy3-tagged anti-rabbit; The Jackson Labora-
tory, Bar Harbor, ME) in the dark for 1 h. Stained cells were
analyzed by using an inverted confocal microscope (Bio-Rad,
Foster City, CA).
Western Blot Analysis. 293T cells were transiently transfected with
MSCV-Cdx4-Neo, MSCV-Cdx4-Neo mutants, andMSCV-Meis1a-
Puro with FuGene according to the manufacturer’s instructions
(Roche Pharmaceuticals, Nutley, NJ). Cells were cultured for 48 h
in DMEM plus 10% FBS and then scraped and lysed in lysis buffer
(150 mMNaCl20 mM Tris5 mM EDTA1% Triton X-100) plus
protease inhibitors (Roche Pharmaceuticals), and protein concen-
tration was estimated by using the Dc protein assay kit (Bio-Rad).
Sixty micrograms of total protein lysate was loaded on 10%
SDSPAGE gels (Invitrogen, Carlsbad, CA) and transferred to a
PVDF membrane. Antibodies against Cdx4 (polyclonal; Aviva
Biosystems, San Diego, CA) and Meis1a (polyclonal; Santa Cruz
Biotechnology, Santa Cruz, CA) were used to detect the respective
proteins.
Patient Samples. We analyzed mononuclear cells prepared from
diagnostic BM or peripheral blood samples from 44 adult patients
with AML. All specimens were karyotyped by chromosome band-
ing and fluorescence in situ hybridization. The diagnosis of AML
was made according to the World Health Organization classifica-
tion of hematological malignancies. All patients gave informed
consent according to the Declaration of Helsinki.
Real-Time qRT-PCR Analysis. Specific murine stem and progenitor
populations were flow-sorted as previously described (25) to de-
termine Cdx4 expression, and RNAwas isolated by using TRIZOL
reagent (Invitrogen) according to the manufacturer’s instructions.
5-Fluorouracil-primed BM enriched for murine hematopoietic
progenitors was transduced with Cdx4 and Cdx4Meis1a or empty
vector and selected for 1 week with G418 (1 mgml) alone (Cdx4
and empty vector) or G418 and puromycin (2.5 gml) (for
Cdx4Meis1a) in liquid culture (RPMI medium 1640 plus 20%
FBS). Total RNA was isolated from BM cells by using TRIZOL
reagent according to the manufacturer’s instructions. cDNA was
prepared by using random hexamers, expression of Cdx4 (primers,
5-CGTGTGGTCTACACAGATCATCAA-3, 5-GGCTCTGC-
GATTCTGAAACC-3; probe, 5-CATCAGGAGGAAGTCA-
GAGCTGGCAGTTA-3) and various Hox genes was assayed by
using a Taqman qRT-PCR method and primers as previously
described (7). For AML primary patient samples, total RNA was
isolated by using the RNeasy Mini Kit (Qiagen, Hilden, Germany)
and was reverse-transcribed (2 g of RNA in a reaction volume of
30 l) by using the TaqMan Gold RT-PCR Kit (Applied Biosys-
tems, Foster City, CA). Quantification of CDX4 expression was
performed by real-time qRT-PCR with primers CDX4 RQ-F
(5-CAA GGC CAG TTC CCC CAG-3) and CDX4 RQ-R
(5-GAA TTC CTT TTC CAG CTC CAA TCT-3) and a 6-car-
boxy-fluorescein-labeled probe (5-FAM-AGG AGC CGC CAC
AGC CCC TAT G-3). For normalization, the porphobilinogen
deaminase gene (PBGD) was used according to the following
formula: CDX4 copy number PBGD copy number 105. CDX4
and PBGD expression levels were determined by absolute mRNA
quantification by using plasmid standard curves. Reactions were
run in duplicate with 2.5 l of cDNA in a total reaction volume of
25 l by using an ABI PRISM 7700 Sequence Detection System
(Applied Biosystems).
Histopathology. Histopathology was performed and analyzed as
described in ref. 25.
Immunophenotypic Analysis of Leukemic Cells. Single-cell suspen-
sions of BM and spleen were prepared and analyzed as described
in ref. 25.
Southern Blot Analysis for Proviral Insertion and Clonality. Tumor
DNA was prepared, digested, electrophoresed, and hybridized as
described in ref. 25. Southern blots were hybridized with probes
designed against the Cdx4 or Meis1a MSCV constructs.
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